Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence-Reference-Cited by-同舟云学术

Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence

Published:2019-05-15 Issue:5 Volume:10 Page:291-303
ISSN:1948-9358
Container-title:World Journal of Diabetes
language:
Short-container-title:WJD

Author:

Pozo Leonardo,Bello Fatimah,Suarez Andres,Ochoa-Martinez Francisco E,Mendez Yamely,Chang Chelsea H,Surani Salim

Publisher

Baishideng Publishing Group Inc.

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference70 articles.

1. World Health Organization. Cardiovascular Diseases (CVDs). 2017. Available from: URL: http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

2. Center for Disease Control and Prevention. Number of Americans with Diabetes Projected to Double or Triple by 2050. 2010. Available from: URL: http://www.cdc.gov/media/pressrel/2010/r101022.html

3. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

4. All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database

5. Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence—A Narrative Review;Cells;2024-09-05

2. Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification;Diabetes & Metabolism Journal;2024-01-31

3. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature;Frontiers in Molecular Biosciences;2023-05-23

4. Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus;Irish Journal of Medical Science (1971 -);2022-12-29

5. Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy;Farmeconomia. Health economics and therapeutic pathways;2022-12-23